Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Acamprosate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acamprosate SCHEMBL41983 | 0.98 | KDM4E (0.65) | KDM4EMAPK1HIF1APAOXADRA1A | |
| Acamprosate SCHEMBL34472814 | 0.96 | KDM4E (0.62) | KDM4EMAPK1HIF1APAOXADRA1A | |
| Acamprosate SCHEMBL347087 | 0.96 | KDM4E (0.62) | KDM4EMAPK1HIF1APAOXADRA1A | |
| Acamprosate SCHEMBL17599929 | 0.96 | KDM4E (0.62) | KDM4EMAPK1HIF1APAOXADRA1A | |
| Acamprosate SCHEMBL7639758 | 0.96 | KDM4E (0.62) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL17754088 | 0.93 | KDM4E (0.65) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL7402850 | 0.91 | KDM4E (0.70) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL7924796 | 0.89 | KDM4E (0.67) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL7523763 | 0.89 | KDM4E (0.67) | KDM4EMAPK1HIF1APAOXADRA1A | |
| Acamprosate SCHEMBL4051464 | 0.85 | KDM4E (0.50) | KDM4EMAPK1HIF1APAOXADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1182837-C | Orally administrable immediate and prolonged-release Galenic form comprising absorption-promoting agent and use of this absorption-promoting agent | Ĭ��ר���ɷ�����˾ | 2005-01-05 | — | — | CN | disclosed |
| EP-1056445-B1 | ORALLY ADMINISTRABLE IMMEDIATE-RELEASE AND PROLONGED-RELEASE GALENIC FORM COMPRISING AN ABSORPTION-PROMOTING AGENT AND USE OF THIS ABSORPTION-PROMOTING AGENT | MERCK PATENT GMBH (DE) | 2004-06-02 | — | — | EP | disclosed |
| EP-1410791-A1 | Orally administrable galenic form comprising metformine and an absorption-promoting agent | MERCK PATENT GmbH (DE) | 2004-04-21 | — | — | EP | disclosed |
| US-6514524-B1 | Improved absorption of hydrophilic ingredients because of particular excipients; calcium 3-acetylamino-1-propane sulfonate (calcium acamprosate); polysorbates, fatty ethers or esters of PEG, polyglycolysed glycerides | MERCK PATENTGESELLSCHAFT MIT (DE) | 2003-02-04 | — | — | US | disclosed |
| US-6426087-B1 | GALENIC FORMS; SUSTAINED RELEASE | MERCK PATENT GESELLSCHAFT MIT (DE) | 2002-07-30 | — | — | US | disclosed |
| US-6265437-B1 | ALCOHOLISM | LIPHA (FR) | 2001-07-24 | — | — | US | disclosed |